Skip to main content
SpringerLink
Log in

31st Hemophilia Symposium

Hamburg 2000

  • Conference proceedings
  • © 2002

Overview

Editors:
  1. Inge Scharrer

    1. Hemophilia Center, Dept. of Internal Medicine, University Hospital, Frankfurt am Main, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Wolfgang Schramm

    1. Dept. of Hemostasiology, University Hospital, München, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (41 papers)

  1. Front Matter

    Pages ii-xxx
    Download chapter PDF

  2. Johann Lukas Schoenlein Award 2000

    1. Johann Lukas Schoenlein Award 2000

      • I. Scharrer
      Pages 1-4

  3. Epidemiology

    1. Front Matter

      Pages 5-5
      Download chapter PDF

    2. HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 1999/2000 Survey)

      • W. Schramm, H. Krebs, the GTH Hemophilia Committee
      Pages 7-14

    3. Hemophilia 2000 — the Annual Survey of the Austrian Hemophilia Centers

      • H. K. Hartl, U. Eidher, U. Kunze, P. Arends, J. Falger, N. D. Jones et al.
      Pages 15-19

  5. Therapy and Monitoring of Bleeds in Acute- and Intensive-Care-Medicine

    1. Front Matter

      Pages 53-53
      Download chapter PDF

    2. Management of Bleeding in Surgery and Intensive Care

      • A. Calatzis, W. Schramm, M. Spannagl
      Pages 55-66

  6. Pediatric Hemostaseology

    1. Front Matter

      Pages 67-67
      Download chapter PDF

    2. Frequency and Profile of viral posttransfusional Infections in Patients from Hemophilia Center Timisoara

      • M. Şerban, C. Petrescu, P. Ţepeneu, M. Pop, S. Jenaru, W. Schramm
      Pages 69-76

    3. Symptomatic Onset of severe Hemophilia A in Childhood is dependent on the Presence of Prothrombotic Risk Factors

      • S. Halimeh, C. Escuriola Ettingshausen, K. Kurnik, R. Schobess, C. Wermes, H. Pollmann et al.
      Pages 77-80

    4. Differences between Neonates and Adults in Plasmin Inhibitory and Antifibrinolytic Action of Aprotinin

      • M. Ries, M. Zenker, J. Klinge
      Pages 81-90

    5. Shorter PFA-100 Closure Times (CT) in Neonates than in Adults: Role of Red Cells, White Cells, Platelets, and von Willebrand Factor

      • B. Roschitz, K. Sudi, W. Muntean
      Pages 91-97

  7. Free Lectures

    1. Front Matter

      Pages 99-99
      Download chapter PDF

    2. Efficacy and Safety of a High Purity Protein C Concentrate in the Management of Patients with severe Congenital Protein C Deficiency

      • B. Moritz, S. Rogy, S. Tonetta, H. P. Schwarz, H. Ehrlich, the CEPROTIN Study Group
      Pages 101-109

    3. Respective Roles of Factors II, VII, IX, and X in the Procoagulant Activity of FEIBA

      • S. Gallistl, G. Cvirn, B. Leschnik, W. Muntean
      Pages 110-113

    4. Capillary Microscopic and Rheological Dimensions for the Diagnosis of von Willebrand Disease in Comparison with other Hemorrhagic Diatheses

      • J. Koscielny, S. Mörsdorf, C. Mrowietz, H. Kiesewetter, U. Budde, U. T. Seyfert et al.
      Pages 114-129
Back to top

Keywords

About this book

Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat­ ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re­ quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat­ ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.

Editors and Affiliations

  • Hemophilia Center, Dept. of Internal Medicine, University Hospital, Frankfurt am Main, Germany

    Inge Scharrer

  • Dept. of Hemostasiology, University Hospital, München, Germany

    Wolfgang Schramm

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation